3-hydroxycyclopentanecarboxaldehyde | 69492-90-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-hydroxycyclopentanecarboxaldehyde
• 英文别名: 3-hydroxycyclopentane aldehyde；3-hydroxy-cyclopentanecarbaldehyde；3-Hydroxy-cyclopentancarbaldehyd；3-Hydroxycyclopentane-1-carbaldehyde
• CAS: 69492-90-6
• 化学式: C₆H₁₀O₂
• 分子量: 114.144
• InChiKey: FWKGSDVDYSPDMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  exo-7-oxabicyclo<2.2.1>hept-yl p-nitrobenzenesulfonate 在 水 作用下， 以 乙醇 为溶剂， 生成 3-hydroxycyclopentanecarboxaldehyde
  参考文献：
  名称：

  降冰片烷。第21部分。降冰片基和氧杂冰片基阳离子中的架桥应变†

  摘要：

  进一步的证据表明，2-降冰片基阳离子主要通过C（2）–C（6）桥接而稳定，而C（2）–C（7）桥接导致抑制性应变。因此，比较了三环戊二烯17和双环的氢化热[3。2. 0. 0. 2.7 ]庚烷18指示后者的应变能是大约21.5更高千卡/摩尔的是那个的17。此外，6 - exo -2--2-氧杂双环[2。2. 1]庚基磺酸盐8与强O（2）参与电离，生成桥连的氧鎓离子12。相反，2-内-7氧杂双环[2.2.1]庚基磺酸盐11在没有O（7）参与的情况下电离，形成未桥连的碳正离子15。

  DOI：

  10.1002/hlca.19880710512

文献信息

• Process for making n-aryl-anthranilic acids and their derivatives
  申请人：——

  公开号：US20040039208A1

  公开（公告）日：2004-02-26

  The present invention relates to a process for the preparation of N-arylanthranilic acids, and a process for the preparation of N-aryl anthranilic esters, amides, and hydroxamic esters.

  本发明涉及一种制备N-芳基蒽酰胺酸的方法，以及制备N-芳基蒽酰酯、酰胺和羟肟酯的方法。
• Highly atom-efficient and chemoselective reduction of ketones in the presence of aldehydes using heterogeneous catalysts
  作者：Yusuke Takahashi、Takato Mitsudome、Tomoo Mizugaki、Koichiro Jitsukawa、Kiyotomi Kaneda

  DOI：10.1039/c3gc41322e

  日期：——

  The first demonstration of a 100% atom-efficient selective reduction of less reactive ketones over aldehydes using heterogeneous catalysts is reported. Extremely high selectivities for intra- and intermolecular reductions of ketones over aldehydes were achieved. This system was also applicable to a column reactor, leading to a gram-scale synthesis.

  100％原子效率选择性的首次演示 减少 反应性较低 酮类 超过 醛类 使用异构 催化剂被报道。分子内和分子间还原异戊二烯的选择性极高酮类 超过 醛类实现了。该系统还适用于柱反应器，导致克级合成。
• Heterocylic antiviral compounds
  申请人：Lemoine Remy

  公开号：US20080103125A1

  公开（公告）日：2008-05-01

  Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R 1 -R 3 and Ar are as defined herein are antagonists of chemokine CCR 5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR 5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.

  化学因子受体拮抗剂，特别是根据公式（I）其中R1-R3和Ar的定义为所定义的3,7-二氮杂双环[3.3.0]辛化合物是化学因子CCR5受体的拮抗剂，可用于治疗或预防人类免疫缺陷病毒（HIV）感染，或治疗艾滋病或ARC。该发明进一步提供了用于治疗通过CCR5拮抗剂缓解的疾病的方法。该发明包括制备公式I化合物的制备方法和用于治疗这些疾病的制药组合物和方法。
• A composition for increasing the anti-cancer activity of an anti-cancer compound
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0180188A2

  公开（公告）日：1986-05-07

  A composition for increasing the anti-cancer activity of an anti-cancer compound selected from among 5-fluorouracil and a compound capable of producing 5-fluorouracil in vivo, the composition comprising an effective amount of a pyridine derivative represented by the formula wherein R1 is hydroxy or acyloxy, R2 and R4 are each hydrogen, halogen, amino, carboxyl, carbamoyl, cyano, nitro, lower alkyl, lower alkenyl or lower alkoxycarbonyl, R3 and R are each hydrogen, hydroxy or acyloxy; when at least one of R1, R3 and R5 is hydroxy, the structure of 1-position on the pyridine rina can be duetothe due to the keto-enol tautomerism, said hydrogen attached to nitrogen being optionally substituted with a substituent selected from the group consisting of lower alkyl, tetrahydrofuranyl, tetrahydropyranyl, lower alkoxy-lower alkyl, phthalidyl, carbamoyl, lower alkoxycarbonyl-lower alkylcarbamoyl, phenyl-lower alkoxy-lower alkyl, phenylcarbamoyl which may have a substituent on the phenyl ring, lower alkylcarbamoyl, carboxy-lower alkylcarbamoyl, lower alkylthio-lower alkyl and lower alkenyl, provided that the compound having the following formula is excluded, wherein a is hydrogen, lower alkyl, tetrahydrofuranyl, tetrahydropyranyl, lower alkoxy-lower alkyl, lower alkylcarbamoyl, lower alkylthio-lower alkyl or lower alkenyl.

  一种提高选自5-氟尿嘧啶和一种能在体内产生5-氟尿嘧啶的化合物的抗癌活性的组合物，该组合物包括有效量的由式表示的吡啶衍生物 其中 R1 是羟基或酰氧基，R2 和 R4 分别是氢、卤素、氨基、羧基、氨基甲酰基、氰基、硝基、低级烷基、低级烯基或低级烷氧基羰基，R3 和 R 分别是氢、羟基或酰氧基；当 R1、R3 和 R5 中至少有一个是羟基时，吡啶里纳上 1 位的结构可以是 当 R1、R3 和 R5 中至少有一个是羟基时，吡啶里纳上 1 位的结构可以是酮烯醇同分异构，所述连接到氮上的氢可选择被选自低烷基、四氢呋喃基、四氢吡喃基、低烷氧基低烷基、邻苯二甲酰基、氨基甲酰基、低烷氧基羰基低烷基氨基甲酰基组成的取代基取代、苯基-低级烷氧基-低级烷基、苯基氨基甲酰基（苯基环上可能有取代基）、低级烷基氨基甲酰基、羧基-低级烷基氨基甲酰基、低级烷硫基-低级烷基和低级烯基，但具有下式的化合物除外、 其中 a 为氢、低级烷基、四氢呋喃基、四氢呋喃基、低级烷氧基低级烷基、低级烷基氨基甲酰基、低级烷硫基低级烷基或低级烯基。
• 5-Fluorouracil derivatives
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0180897B1

  公开（公告）日：1991-08-07